Novel formulations of oral bisphosphonates in the treatment of osteoporosis
This report describes the result of an ESCEO (European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis) expert working group, which explores where oral bisphosphonates sit in current clinical practice guidelines, review their risk-benefit profile and the consequences of poor adherence before exploring novel oral bisphosphonate formulations and their potential clinical and health economic impact. Further research is required but there are signs that these novel, oral bisphosphonate formulations may lead to improved tolerance of oral bisphosphonates and thus, improved adherence and fracture outco...
Source: Aging Clinical and Experimental Research - November 4, 2022 Category: Geriatrics Authors: Nicholas Fuggle Nasser Al-Daghri Olivier Bock Jaime Branco Olivier Bruy ère Enrique Casado Etienne Cavalier Bernard Cortet Maarten de Wit Andrea Giusti Philippe Halbout Nicholas C Harvey Micka ël Hiligsmann Jean-Marc Kaufman Andreas Kurth Stefania Maggi Source Type: research
Comparisons between different anti-osteoporosis medications on postfracture mortality: A population-based study
CONCLUSION: This real-world mega data study suggests that the usage of osteoporotic medication, especially the long-acting regimen, may lower postfracture mortality.PMID:36317591 | DOI:10.1210/clinem/dgac636 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - November 1, 2022 Category: Endocrinology Authors: Chih-Hsing Wu Chia-Chun Li Yu-Hsuan Hsu Fu-Wen Liang Yin-Fan Chang Jawl-Shan Hwang Source Type: research
Comparisons between different anti-osteoporosis medications on postfracture mortality: A population-based study
CONCLUSION: This real-world mega data study suggests that the usage of osteoporotic medication, especially the long-acting regimen, may lower postfracture mortality.PMID:36317591 | DOI:10.1210/clinem/dgac636 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - November 1, 2022 Category: Endocrinology Authors: Chih-Hsing Wu Chia-Chun Li Yu-Hsuan Hsu Fu-Wen Liang Yin-Fan Chang Jawl-Shan Hwang Source Type: research
Medication-Related Osteonecrosis of the Jaw: 14 Years’ Retrospective Study on Pathogenetic Trigger Events
Although events such as tooth extraction and oral surgery were considered for a while the sole triggering factor for Medication-Related Osteonecrosis of the Jaw (MRONJ), it is still unclear if trigger events may be precipitating factors that accelerate the onset of the disease that would have possibly occurred anyway. Therefore, this research aimed to retrospectively analyze MRONJ cases diagnosed in our tertiary referral hospital during the last 14 years, focusing on the onset of the disease, potential trigger events, and countermeasures to update the knowledge on their pathogenesis. An audit of patients diagnosed with MRO...
Source: Journal of Craniofacial Surgery - October 1, 2022 Category: Surgery Tags: Brief Clinical Studies Source Type: research
Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis
CONCLUSION: Denosumab effectively reduced the risk of vertebral fractures in men with osteoporosis, and this effect was comparable to that of bisphosphonates.PMID:36149052 | DOI:10.25011/cim.v45i3.38875 (Source: Clinical and Investigative Medicine)
Source: Clinical and Investigative Medicine - September 23, 2022 Category: Biomedical Science Authors: Pengfei Li Xiaojian Wu Ye Li Jianhua Huang Source Type: research
Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis
CONCLUSION: Denosumab effectively reduced the risk of vertebral fractures in men with osteoporosis, and this effect was comparable to that of bisphosphonates.PMID:36149052 | DOI:10.25011/cim.v45i3.38875 (Source: Clinical and Investigative Medicine)
Source: Clinical and Investigative Medicine - September 23, 2022 Category: Biomedical Science Authors: Pengfei Li Xiaojian Wu Ye Li Jianhua Huang Source Type: research
Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis
CONCLUSION: Denosumab effectively reduced the risk of vertebral fractures in men with osteoporosis, and this effect was comparable to that of bisphosphonates.PMID:36149052 | DOI:10.25011/cim.v45i3.38875 (Source: Clinical and Investigative Medicine)
Source: Clinical and Investigative Medicine - September 23, 2022 Category: Biomedical Science Authors: Pengfei Li Xiaojian Wu Ye Li Jianhua Huang Source Type: research
Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis
CONCLUSION: Denosumab effectively reduced the risk of vertebral fractures in men with osteoporosis, and this effect was comparable to that of bisphosphonates.PMID:36149052 | DOI:10.25011/cim.v45i3.38875 (Source: Clinical and Investigative Medicine)
Source: Clinical and Investigative Medicine - September 23, 2022 Category: Biomedical Science Authors: Pengfei Li Xiaojian Wu Ye Li Jianhua Huang Source Type: research
Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis
CONCLUSION: Denosumab effectively reduced the risk of vertebral fractures in men with osteoporosis, and this effect was comparable to that of bisphosphonates.PMID:36149052 | DOI:10.25011/cim.v45i3.38875 (Source: Clinical and Investigative Medicine)
Source: Clinical and Investigative Medicine - September 23, 2022 Category: Biomedical Science Authors: Pengfei Li Xiaojian Wu Ye Li Jianhua Huang Source Type: research
Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis
CONCLUSION: Denosumab effectively reduced the risk of vertebral fractures in men with osteoporosis, and this effect was comparable to that of bisphosphonates.PMID:36149052 | DOI:10.25011/cim.v45i3.38875 (Source: Clinical and Investigative Medicine)
Source: Clinical and Investigative Medicine - September 23, 2022 Category: Biomedical Science Authors: Pengfei Li Xiaojian Wu Ye Li Jianhua Huang Source Type: research
Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis
CONCLUSION: Denosumab effectively reduced the risk of vertebral fractures in men with osteoporosis, and this effect was comparable to that of bisphosphonates.PMID:36149052 | DOI:10.25011/cim.v45i3.38875 (Source: Clinical and Investigative Medicine)
Source: Clinical and Investigative Medicine - September 23, 2022 Category: Biomedical Science Authors: Pengfei Li Xiaojian Wu Ye Li Jianhua Huang Source Type: research
Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis
CONCLUSION: Denosumab effectively reduced the risk of vertebral fractures in men with osteoporosis, and this effect was comparable to that of bisphosphonates.PMID:36149052 | DOI:10.25011/cim.v45i3.38875 (Source: Clinical and Investigative Medicine)
Source: Clinical and Investigative Medicine - September 23, 2022 Category: Biomedical Science Authors: Pengfei Li Xiaojian Wu Ye Li Jianhua Huang Source Type: research
Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis
CONCLUSION: Denosumab effectively reduced the risk of vertebral fractures in men with osteoporosis, and this effect was comparable to that of bisphosphonates.PMID:36149052 | DOI:10.25011/cim.v45i3.38875 (Source: Clinical and Investigative Medicine)
Source: Clinical and Investigative Medicine - September 23, 2022 Category: Biomedical Science Authors: Pengfei Li Xiaojian Wu Ye Li Jianhua Huang Source Type: research
Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis
CONCLUSION: Denosumab effectively reduced the risk of vertebral fractures in men with osteoporosis, and this effect was comparable to that of bisphosphonates.PMID:36149052 | DOI:10.25011/cim.v45i3.38875 (Source: Clinical and Investigative Medicine)
Source: Clinical and Investigative Medicine - September 23, 2022 Category: Biomedical Science Authors: Pengfei Li Xiaojian Wu Ye Li Jianhua Huang Source Type: research
Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis
CONCLUSION: Denosumab effectively reduced the risk of vertebral fractures in men with osteoporosis, and this effect was comparable to that of bisphosphonates.PMID:36149052 | DOI:10.25011/cim.v45i3.38875 (Source: Clinical and Investigative Medicine)
Source: Clinical and Investigative Medicine - September 23, 2022 Category: Biomedical Science Authors: Pengfei Li Xiaojian Wu Ye Li Jianhua Huang Source Type: research
